Physician profile
John Callahan
NPI 1609988393
$2,796.65
in general payments reported to CMS, 2019-2025
27 companies · $755 in 2025
The $755 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $188 · 2021: $387 · 2022: $54.76 · 2023: $392 · 2024: $891 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $345.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $312.87 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $268.01 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $262.85 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $232.30 | 2019-2025 | |
| Amgen INC. | $207.28 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $181.82 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $155.84 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $109.30 | 2019-2024 | |
| Abbvie INC. | $106.35 | 2023-2025 | Ubrelvy, Vraylar |
| Skeletal Dynamics INC | $99.87 | 2021 | |
| Supernus Pharmaceuticals, INC. | $88.13 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $46.46 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $46.07 | 2020 | |
| Viatris Specialty LLC | $45.84 | 2025 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $37.96 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $36.50 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $34.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.83 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.41 | 2020 | |
| Dynavax Technologies Corporation | $23.96 | 2024 | Heplisav-B |
| Grifols USA, LLC | $22.99 | 2025 | Prolastin-C Liquid |
| Biodelivery Sciences International, INC. | $18.64 | 2021 | |
| Corcept Therapeutics | $17.72 | 2024 | Korlym |
| Exact Sciences Corporation | $15.11 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.